Geneoscopy
Geneoscopy is dedicated to transforming gastrointestinal health through innovative, noninvasive diagnostic tests. Founded by siblings Andrew and Erica Barnell, the company leverages proprietary stool-derived eukaryotic RNA (seRNA) technology to develop tests for colorectal cancer and other GI diseases. With FDA-approved ColoSense™ test and strategic partnerships, Geneoscopy aims to improve early detection, treatment, and monitoring of gastrointestinal conditions, ultimately enhancing patient outcomes and health equity.
Industries
Nr. of Employees
medium (51-250)
Geneoscopy
Saint Louis, Missouri, United States, North America
Products
Noninvasive multi-target stool RNA colorectal cancer screening test
A laboratory-performed stool-based assay that qualitatively detects colorectal neoplasia-associated RNA markers and occult hemoglobin to screen average-risk adults for colorectal cancer and advanced precancerous lesions.
Noninvasive multi-target stool RNA colorectal cancer screening test
A laboratory-performed stool-based assay that qualitatively detects colorectal neoplasia-associated RNA markers and occult hemoglobin to screen average-risk adults for colorectal cancer and advanced precancerous lesions.
Services
Clinical diagnostic laboratory testing (stool RNA-based CRC screening)
Provision of a single-site clinical laboratory service performing stool-derived RNA and occult hemoglobin testing for colorectal cancer screening in average-risk adults.
Analytical validation and regulatory support
Execution of analytical validation studies and preparation/support of regulatory submissions to health authorities for diagnostic assays.
Biopharma research partnerships and trial sample procurement
Integration of at-home stool collection into clinical studies, provision of sample processing and molecular readouts, and support for companion diagnostic or therapeutic monitoring tool development.
Machine-learning biomarker analytics
Application of machine-learning models to transcriptomic data from stool to produce classifiers for disease detection, activity monitoring, and severity stratification.
Stool biobank access and sample analysis
Access to a curated stool sample biobank and associated molecular characterization to support R&D, validation studies, and exploratory research.
Clinical diagnostic laboratory testing (stool RNA-based CRC screening)
Provision of a single-site clinical laboratory service performing stool-derived RNA and occult hemoglobin testing for colorectal cancer screening in average-risk adults.
Analytical validation and regulatory support
Execution of analytical validation studies and preparation/support of regulatory submissions to health authorities for diagnostic assays.
Biopharma research partnerships and trial sample procurement
Integration of at-home stool collection into clinical studies, provision of sample processing and molecular readouts, and support for companion diagnostic or therapeutic monitoring tool development.
Machine-learning biomarker analytics
Application of machine-learning models to transcriptomic data from stool to produce classifiers for disease detection, activity monitoring, and severity stratification.
Stool biobank access and sample analysis
Access to a curated stool sample biobank and associated molecular characterization to support R&D, validation studies, and exploratory research.
Expertise Areas
- RNA-based stool diagnostics
- Clinical trial management for diagnostic assays
- Analytical assay validation and performance characterization
- Clinical laboratory operations (CLIA/CAP) and state permitting
Key Technologies
- Stool-derived eukaryotic RNA analysis
- At-home stool collection kits
- Next-generation sequencing (NGS)
- Droplet digital PCR (ddPCR)